Pre-Exposure Prophylaxis for HIV Prevention in Those with Substance Use Disorders

Nancy Goldstein*, Jared Carter-Davis**, Ellen C. Seymour***
* Assistant Professor, School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
**-*** Graduate Student, School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
Periodicity:May - July'2018
DOI : https://doi.org/10.26634/jnur.8.2.14022

Abstract

In 2012, Truvada, the medication used for Pre-exposure Prophylaxis (PrEP) was approved by the Food and Drug Administration (FDA) for use as human Immunodeficiency Virus (HIV) prevention by those at high-risk of viral acquisition through sexual practices. Since then, it has been found to be an effective prevention modality for multiple high-risk populations, including those with Substance Use Disorders (SUD), yet most of the research on PrEP has focused on use among men who have sex with men. In an effort to consolidate the existing evidence on PrEP use among those with SUD, a systematic review was performed and areas of established insight, in addition to those in which such insight is lacking, were identified. The present study is a systematic review of publications related to both HIV pre-exposure prophylaxis and substance use disorder. It was conducted according to the Preferred Reporting Items for Systematic Review and Meta- Analyses (PRISMA) guidelines.

A total of 107 distinct articles were extracted from three databases and 11 articles were selected for final review based on criteria designed to meet the objectives of the study. Eleven studies (five cross-sectional, three qualitative, two literature reviews, and one commentary) were ultimately selected as the most relevant evidence on the topic to date. Numerous gaps exist in the literature, including a lack of research on the implementation of PrEP uptake initiatives in the context of a SUD treatment center. Further research is needed to examine the efficacy of the different methodologies for expanding PrEP access in such settings.

Keywords

Substance Use, Drug Use, Pre-Exposure Prophylaxis (PrEP), HIV Prevention.

How to Cite this Article?

Goldstein,N., Davis,J,C., and Seymour,E.C .(2018). Pre-Exposure Prophylaxis for HIV Prevention in Those with Substance Use Disorders.i-manager’s Journal on Nursing, 8(2),7-13. https://doi.org/10.26634/jnur.8.2.14022

References

[1]. Bernard, C. L., Owens, D. K., Goldhaber-Fiebert, J. D., & Brandeau, M. L. (2017). Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis. PLoS Medicine, 14(5), 1-19.
[2]. Biello, K. B., Oldenburg, C. E., Mitty, J. A., Closson, E. F., Mayer, K. H., Safren, S. A., & Mimiaga, M. J. (2017). The “Safe Sex” conundrum: Anticipated stigma from sexual partners as a barrier to PrEP use among substance using MSM engaging in transactional sex. AIDS and Behavior, 21(1), 300-306.
[3]. Centers for Disease Control and Prevention. (2014). Preexposure prophylaxis for the prevention of HIV infection in the United States-2014: A clinical practice guideline. Atlanta: Centers for Disease Control and Prevention, 1-67.
[4]. Centers for Disease Control and Prevention (2018). HIV and substance use in the United States. Retrieved from https://www.cdc.gov/hiv/risk/substanceuse.html
[5]. Coleman, R. L., & McLean, S. (2016). Commentary: The value of PrEP for people who inject drugs. Journal of the International AIDS Society, 19(6), 1-5.
[6]. Escudero, D. J., Lurie, M. N., Kerr, T., Howe, C. J., & Marshall, B. D. (2014). HIV pre-exposure prophylaxis for people who inject drugs: A review of current results and an agenda for future research. Journal of the International AIDS Society, 17(1), 1-5.
[7]. House, W. (2015). National HIV/AIDS strategy for the United States: Updated to 2020. Washington, DC. Retrieved from www.hiv/gov/sites/default/files/nhas-update.pdf
[8]. Martin, M., Vanichseni, S., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., ... & Kittimunkong, S. (2015). The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS, 29(7), 819-824.
[9]. Mimiaga, M. J., Closson, E. F., Kothary, V., & Mitty, J. A. (2014). Sexual partnerships and considerations for HIV antiretroviral pre-exposure prophylaxis utilization among high-risk substance using men who have sex with men. Archives of Sexual Behavior, 43(1), 99-106.
[10]. Oldenburg, C. E., Mitty, J. A., Biello, K. B., Closson, E. F., Safren, S. A., Mayer, K H.., & Mimiaga, M. J. (2016). Differences in attitudes about HIV pre-exposure - prophylaxis use among stimulant versus alcohol using men who have sex with men. AIDS Behav., 20(7), 1451-1460.
[11]. Page, K., Tsui, J., Maher, L., Choopanya, K., Vanichseni, S., Mock, P. A., ... & Martin, M. (2015). Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: State of research and future directions. Journal of Acquired Immune Deficiency Syndromes, 69(1), 169- 175.
[12]. Shrestha, R., Altice, F. L., Huedo-Medina, T. B., Karki, P., & Copenhaver, M. (2017a). Willingness to use pre-exposure prophylaxis (PrEP): An empirical test of the information-motivation- behavioral skills (IMB) model among high-risk drug users in treatment. AIDS and Behavior, 21(5), 1299- 1308.
[13]. Shrestha, R., Karki, P., Altice, F. L., Huedo-Medina, T. B., Meyer, J. P., Madden, L., & Copenhaver, M. (2017b). Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug-and sex-related behaviors among high-risk drug users on methadone treatment. Drug and Alcohol Dependence, 173, 107-116.
[14]. Spector, A. Y., Remien, R. H., & Tross, S. (2015). PrEP in substance abuse treatment: A qualitative study of treatment provider perspectives. Substance Abuse Treatment, Prevention, And Policy, 10(1), 1-10.
[15]. Stein, M., Thurmond, P., & Bailey, G. (2014). Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS and Behavior, 18(9), 1694-1700.

Purchase Instant Access

Single Article

North Americas,UK,
Middle East,Europe
India Rest of world
USD EUR INR USD-ROW
Pdf 35 35 200 20
Online 35 35 200 15
Pdf & Online 35 35 400 25

If you have access to this article please login to view the article or kindly login to purchase the article
Options for accessing this content:
  • If you would like institutional access to this content, please recommend the title to your librarian.
    Library Recommendation Form
  • If you already have i-manager's user account: Login above and proceed to purchase the article.
  • New Users: Please register, then proceed to purchase the article.